Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients with Metastatic Renal Cancer

This is a randomized, phase II study of IL-2 and SBRT in patients with metastatic renal cancer.

Key Eligibility:
• Histological confirmation of predominant conventional (clear cell) renal cancer will be required by previous biopsy or cytology.
• Tumors amenable to SBRT in lungs (central locations preferred), mediastinum, chest wall, bones with a soft tissue component (other than long bones), or liver, liver hilum and associated lymph nodes (inclusive of immediately adjacent masses), 1 – 3 foci; no minimum size, but none greater than 7 cm. Patients may have other metastases but only a maximum of 3 will be treated.
• ECOG 0 or 1
Phase II
Brendan Curti, M.D.
Earle A Chiles Research Institute (EACRI)
Scot Lary
  • Oncology and Hematology Care Eastside